China granted Grand Pharmaceutical's (HKG:0512) nuclear medicine research and development and production facility in Wenjiang, Chengdu, China, obtained a class A radiation safety license.
The facility will start operating in June this year after passing the environmental assessment conducted in April 2023, according to a Sunday filing with the Hong Kong bourse.
Grand Pharma invested more than 3 billion yuan for the facility, which will focus on isotope process development and preparation, nuclear medicine coupling technology, and automated labeling technology, the filing said.